TGFB1 and idiopathic pulmonary fibrosis: Although the outcomes of fibrosis in these two conditions often differ, studying these shared mechanisms may inform the development of therapeutic strategies, such as TGF-β1-targeted therapies in the treatment of COVID-19 and IPF (Budi et al., 2021; P et al., 2021).